Skip to main content

Development and clinical validation of a multiplex PCR-based targeted next-generation sequencing panel for simultaneous DNA/RNA pathogen detection in respiratory tract infections: a comprehensive performance evaluation

Journal
Clinical chemistry and laboratory medicine (Q1)
Published
12 November 2026
Study design
Unclassified
Evidence level
Level 5, Expert Opinion (CEBM 5)
Authors
Juan Long, Xiaoyan Tao, Junli Wang, Shenhui Yang, Dandan Tie, Li Jiang, et al.
PMID
43015262
DOI
10.1515/cclm-2026-0540

Why clinicians should know about it

  • Picked for Microbiology (medical) (top studies of the week, 15 November 2026): Clinical respiratory pathogen panel validates detection and resistance prediction

Abstract

OBJECTIVES: Lower respiratory tract infections (LRTI) remain a leading cause of global morbidity and mortality, with approximately 62 % of cases lacking definitive etiological diagnoses via conventional methods. This study aimed to develop and validate a multiplex PCR-based targeted next-generation sequencing (mp-tNGS) panel for comprehensive pathogen detection in respiratory samples. METHODS: We conducted a combined retrospective (n=209) and prospective (n=256) study involving 465 bronchoalveolar lavage fluid (BALF) samples from patients with suspected LRTI. The mp-tNGS panel was designed to detect 277 clinically relevant pathogens, integrating simultaneous DNA/RNA co-detection and single-nucleotide polymorphism (SNP)-based contamination control. Diagnostic performance was evaluated against conventional microbiological tests (CMTs) and metagenomic next-generation sequencing (mNGS). RESULTS: The mp-tNGS assay revealed a limit of detection (LoD) of 25 copies/mL for bacteria/fungi and 50 copies/mL for viruses, with acceptable precision (intrabatch CV=9.42 %; interbatch CV=26.03 %). A novel SNP-based bioinformatics pipeline achieved exceptional discriminative performance (AUC=0.992) for distinguishing true infections from contamination. Compared with CMTs and mNGS, mp-tNGS showed superior sensitivity (93.59 %, 95 % CI: 90.81-95.73 %), particularly for viruses (AUC=0.92 vs. 0.845). The assay reliably identified fastidious pathogens (e.g., Pneumocystis jirovecii and Legionella pneumophila) and predicted antimicrobial resistance (97.08 % concordance with phenotypic testing). CONCLUSIONS: We developed an mp-tNGS panel with diagnostic performance comparable to that of mNGS. The panel integrates broad pathogen coverage, rapid turnaround time, machine learning-based false-positive reduction, and concordance with phenotypic susceptibility testing, positioning it as a promising molecular diagnostic tool for LRTI.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.